# Platelet Hyperreactivity as a Therapeutic Target for Reducing Stroke in Older Adults after Transcatheter Aortic Valve Replacement

> **NIH NIH R03** · UNIVERSITY OF COLORADO DENVER · 2020 · $155,500

## Abstract

The long term goal of the proposal is to determine the role of aging-associated platelet hyperreactivity for
increasing stroke risk after transcatheter aortic valve replacement in older adults. More than 60,000 people
undergo cardiac surgery in the United States each year which allows them to live longer and more fulfilling
lives, but if the procedure is complicated by stroke mortality increases up to 10-fold. Dr. Clendenen is a
Cardiothoracic Anesthesiologist dedicated to improving clinical outcomes after cardiac procedures for older
adults and this NIA GEMSSTAR proposal is designed to provide him with the structured mentorship and
training necessary to become a leader in perioperative aging research. He has developed a collaborative
mentorship team led by Dr. Adit Ginde who is an Emergency Medicine Physician and national PI for a large
PETAL network clinical trial with 3,000 participants, with co-mentorship provided by Dr. Robert Schwartz, , a
recognized leader in aging research. Methodological advisors include Dr. Alex Kaizer (Biostatistics) and Dr.
Kirk Hansen (Thrombosis). This proposal leverages the collective expertise of an established mentorship team
and the unique environment at the University of Colorado Anschutz Medical Center that incorporates a tertiary
referral center for cardiac procedures in the setting of a large public research University. These ample
resources will allow Dr. Clendenen to address key barriers to reducing stroke risk after transcatheter aortic
valve replacement with a large retrospective cohort study collecting data from 50 institutions across 19 states
(Multicenter Perioperative Outcomes Group, MPOG, n >14,000) and a prospective observational cohort with in
depth platelet hyperreactivity analysis (n = 100). He will accomplish this by determining the association
between aging associated platelet hyperreactivity and in-hospital stroke after TAVR with MPOG (Aim 1) and
determining the detrimental effect of TAVR on aging-associated platelet hyperreactivity with the prospective
cohort (Aim 2). These specific aims require Dr. Clendenen to develop expertise in analyzing large datasets and
aging research. He will accomplish this with a focused Professional Development Plan including coursework
on biostatistics, clinical study design, and aging research. Completion of the proposed project will provide the
necessary mentorship, training, and experience required to allow Dr. Clendenen to become a leader in
perioperative aging research to improve outcomes after transcatheter aortic valve replacement.

## Key facts

- **NIH application ID:** 10027770
- **Project number:** 1R03AG067984-01
- **Recipient organization:** UNIVERSITY OF COLORADO DENVER
- **Principal Investigator:** Nathan Clendenen
- **Activity code:** R03 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $155,500
- **Award type:** 1
- **Project period:** 2020-09-15 → 2022-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10027770

## Citation

> US National Institutes of Health, RePORTER application 10027770, Platelet Hyperreactivity as a Therapeutic Target for Reducing Stroke in Older Adults after Transcatheter Aortic Valve Replacement (1R03AG067984-01). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10027770. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*